D45 Polycythemia vera

Name of the Condition

• Polycythemia vera

Summary

Polycythemia vera is a rare, chronic myeloproliferative neoplasm characterized by the overproduction of red blood cells in the bone marrow. This excess production can lead to increased blood viscosity, raising the risk of thrombotic events or bleeding complications. The condition may also involve elevated levels of white blood cells and platelets.

Causes

The exact cause of polycythemia vera is not fully understood, but it is associated with a somatic mutation in the JAK2 gene (JAK2 V617F) in most cases. This mutation affects the signaling pathways that regulate blood cell production, leading to uncontrolled proliferation of hematopoietic cells.

Risk Factors

• Age (more common in adults over 60)
• Male gender (slightly higher prevalence)
• Family history of myeloproliferative disorders

Symptoms

• Headaches, dizziness, or blurred vision
• Itching (especially after warm baths)
• Fatigue or weakness
• Shortness of breath or chest pain
• Abdominal discomfort (due to splenomegaly)
• Unusual bleeding or bruising
• Reddish skin tone (plethora)

Diagnosis

Diagnosis typically involves a combination of laboratory tests, including a complete blood count (CBC) to assess elevated red blood cell mass, hematocrit, and hemoglobin levels. Additional tests may include bone marrow biopsy, JAK2 mutation analysis, and serum erythropoietin (EPO) levels. Imaging or ultrasound may be used to evaluate splenomegaly.

Treatment Options

Treatment aims to reduce blood volume and prevent complications. Phlebotomy (blood removal) is commonly used to lower hematocrit. Medications such as hydroxyurea or interferon-alpha may be prescribed to suppress bone marrow activity. Aspirin is often recommended to reduce thrombotic risk, and targeted therapies (e.g., JAK inhibitors) may be used in refractory cases.

Prognosis and Follow-Up

With proper management, many patients have a normal life expectancy. Regular monitoring of blood counts and symptoms is essential to adjust treatment and detect complications early. Follow-up visits typically occur every 3–6 months, with more frequent checks during treatment initiation or changes.

Complications

• Thrombotic events (e.g., stroke, heart attack, deep vein thrombosis)
• Hemorrhagic complications (e.g., gastrointestinal bleeding)
• Splenomegaly or splenic infarction
• Progression to myelofibrosis or acute leukemia (rare)

Lifestyle & Prevention

• Stay hydrated to reduce blood viscosity
• Avoid smoking or excessive alcohol use
• Engage in regular physical activity (as tolerated)
• Monitor for symptoms and report changes promptly
• Follow prescribed treatment regimens consistently

When to Seek Professional Help

Seek immediate medical attention for:

• Sudden severe headache, chest pain, or shortness of breath
• Unexplained bruising, bleeding, or vision changes
• Signs of infection (e.g., fever, chills)
• Persistent or worsening symptoms despite treatment

Tips for Medical Coders

When coding for polycythemia vera (ICD-10-CM code D45), ensure documentation supports the diagnosis, including laboratory findings (e.g., elevated hematocrit, JAK2 mutation) and clinical symptoms. Differentiate from secondary polycythemia (e.g., due to hypoxia) by verifying the absence of underlying causes. Document any complications or treatment plans to support accurate code assignment.